Compare STKS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | PMVP |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 66.1M |
| IPO Year | 2011 | 2020 |
| Metric | STKS | PMVP |
|---|---|---|
| Price | $1.83 | $1.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.70 | N/A |
| AVG Volume (30 Days) | 16.4K | ★ 298.6K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.65 | $1.02 |
| 52 Week High | $3.38 | $1.88 |
| Indicator | STKS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 52.66 |
| Support Level | $1.69 | $1.04 |
| Resistance Level | $1.97 | $1.26 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 77.27 | 70.69 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.